US OptionsDetailed Quotes
IMMP240816P7500
- 4.70
- 0.000.00%
15min DelayTrading Jul 15 09:46 ET
0.00High0.00Low
0.00Open4.70Pre Close0 Volume2 Open Interest7.50Strike Price0.00Turnover507.55%IV-43.59%PremiumAug 16, 2024Expiry Date5.55Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6356Delta0.1446Gamma0.34Leverage Ratio-0.0195Theta-0.0033Rho-0.22Eff Leverage0.0020Vega
Immutep Stock Discussion
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For Anti-PD-1 Therapy
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, and sta...
Benzinga· 5 mins ago
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearanc...
No comment yet